Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Face Steady often a winner .
RNS Brought GDR back on purchasers list .How soon they next one drops .
Volume needs to increase dramatically though for us to get to 30p.
I will be a lot more comfortable when we are back over 30p Then an update on the progress of AIHL would be nice!
Another tick up coming
Something's brewing ?...
Tickin up .
1 RNS .Can AIHL be expected after a short time .
Promoting of AIHL impressive . Low number of Tweets of other tests .Where did Government buy large percentage of Covid tests China .
Rare agree with post .Excellent promotion of AIHL test . Also recent backing from NHS .£1 or higher .
Reason why low numbers prepared to sell at this price ,Who wants to miss out if RNS .
NHS Https: // lnkd.in / ddVenf _K
Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.
Excellent Brighty .
Observe this rocket when good news .
When you read the amazing comments in the NHS press release from key players such as:
* National Medical Director Stephen Powis
* Chief Scientific Officer for England Professor Dame Sue Hill
* Minister for Innovation Lord Kamall
* & Director of Policy and Campaigns at the National Deaf Children’s Society Mike Hobday
You have to conclude that purchase orders from the NHS must be coming GDR's way soon.
A quick reminder of what the key players said a few weeks ago about GDR:
* NHS national medical director Stephen Powis: “The successful trial of this bedside test is fantastic news for the hundreds of babies – and their parents – who would otherwise lose their hearing when given this common antibiotic in intensive care situations. Through world-class innovation, the NHS is delivering cutting edge treatments to save and improve patients’ lives as well as delivering on the commitments of the NHS Long Term Plan.”
* Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS: “Genomic medicine is transforming healthcare, and this is a powerful example of how genetic testing can now be done extremely quickly and become a vital part of triage – not only in intensive care but across our services.
“It also shows the importance of thinking about how advances in technology can rapidly transform how we use genomics closer to care for our patients.”
* Mike Hobday, Director of Policy and Campaigns at the National Deaf Children’s Society: “The National Deaf Children’s Society welcomes the publication of this important study. The introduction of a rapid test to identify susceptibility to deafness caused by the antibiotic gentamicin will be greatly valued by many families of newborn babies.
“Up to now the genetic test has taken too long to return from the lab to be useful for babies requiring urgent treatment but a rapid test will be a game-changer”.
* Minister for Innovation, Lord Kamall: “Genomics is changing the future of healthcare – from detecting new variants of Covid to enabling more targeted treatment of illness.
“This innovative new test has the potential to prevent life altering and preventable side effects for babies and keep the NHS ahead of the curve in delivering state of the art care. The UK continues to lead the way in genomics expertise and is paving the way for earlier diagnosis of conditions in children and faster access to the right treatment”.
Good luck, Brighty